Status:
UNKNOWN
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
Lead Sponsor:
Genomas, Inc
Collaborating Sponsors:
Hartford Hospital
University of Kentucky
Conditions:
Psychoses
Eligibility:
All Genders
18-59 years
Brief Summary
The purpose of this study is to assess patients treated with the antipsychotics aripiprazole (Abilify®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), or ziprasidone (Geodon...
Detailed Description
As many as 30% of psychiatric patients experience weight gain, central deposition of fat, dyslipidemia, increased blood glucose and hypertension--diabetic metabolic symptoms--upon treatment with atypi...
Eligibility Criteria
Inclusion
- receiving atypical antipsychotic therapy (olanzapine, aripiprazole, quetiapine, risperidone, or ziprasidone) for 3 months
- who have taken \>50% of the prescribed dose for the last month.
Exclusion
- none
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00752960
Start Date
January 1 2007
End Date
December 1 2009
Last Update
September 16 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hartford Hospital Institute of Living
Hartford, Connecticut, United States, 06106
2
University of Kentucky
Lexington, Kentucky, United States, 40508